FLOW showed semaglutide reduced major kidney disease events by 24%, strengthening the case for GLP-1 RAs as part of cardiorenal-metabolic care
statistically significant improvement in motor symptoms Another trial with once-daily self-administered injections of liraglutide (1.2 or 1.8 mg, as tolerated) or placebo in 62 patients with PD reported improvements in MDS-UPDRS-2 (an activity of daily living scale), but not in MDS-UPDRS-3, in treated patients vs placebo
They can also suggest an eating pattern and exercise plan to support your health goals and preferences
"Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease." Neurology
Ensure the medication is stored strictly out of reach and out of sight of children and pets
GLP-1 medical weight management may be considered for adults who are overweight or obese, especially if weight is affecting metabolic health, cardiovascular risk, or overall wellbeing